- CSR Summary Not Yet Available
- NCT02489318
- Primary Citation
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameApalutamideProduct NameERLEADA®Therapeutic AreaCancers and Other NeoplasmsEnrollment1052% FemaleN/A% White68.3%
Product ClassNonsteroidal antiandrogenSponsor Protocol Number56021927PCR3002Data PartnerJohnson & JohnsonCondition StudiedNeoplasms, ProstaticMean/Median Age (Years)68.4
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0836 : Patterns of metastasis appearance and prognostic differences based on the type of metastasis in metastatic, castration-sensitive prostate cancer
- 2024-0784 : Investigating the Canonical Polycomb Repressive Complex 1 (cPRC1) as an Intrinsic Mechanism of Resistance to Apalutamide in Advanced Prostate Cancer
- 2024-0392 : Missing data considerations for patient reported outcome measures in randomized controlled trials
- 2024-0136 : Volume of bone metastasis and outcomes of apalutamide in patients with metastatic castration-sensitive prostate cancer
- 2023-5534 : Quality tolerance limit and duplicated patient investigation in clinical trials
- 2023-5274 : Statin use and outcomes in patients treated in the SPARTAN, TITAN and ACIS trial
- 2023-5242 : Patterns of disease progression in patients with metastatic, castration-sensitive prostate cancer
- 2023-5215 : Analysis of adverse events of prostate cancer drugs targeting on the hypothalamic pituitary gonadal axis
- 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
- 2023-5187 : The association between antibiotics exposure and outcomes in men with prostate cancer
- 2023-5173 : Improving Outcome in Advanced Prostate Cancer: a Pooled Analysis of Randomized Controlled Trials